5 Key Sessions at the American Diabetes Association 84th Scientific Sessions

Pharmacy Times® will be covering the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida from June 21 to June 24, 2024. ADA’s annual meeting is the largest diabetes conference, according to their website. It will include in-person networking opportunities, scientific advances, groundbreaking research presentations, and poster sessions. Areas that will be covered at the meeting will include acute and chronic complications, behavioral medicine, clinical nutrition, education, exercise, clinical diabetes and therapeutics, epidemiology, immunology, insulin action, obesity, and insulin secretion.

Image Credit: aiisha - stock.adobe.com

Stay tuned on pharmacytimes.com for exclusive session coverage and interviews with presenters, such as:

• A presentation featuring the results of the SURMOUNT-OSA trial, as well as the role of tirzepatide in treating obesity related obstructive sleep apnea (OSA). The session will include the current landscape for treating OSA, how the study was designed, the efficacy and safety analyses, and the implication of this treatment for patients who have obesity-related OSA. Presenters include Ania M. Jastreboff, MD, PhD, Atul Malhotra, MD, Esra Tasali, MD, Vaishnavi Kundel, MD, MS, Richard J. Schwab, MD, and Louis J. Aronne, MD, FACP, DABOM.
• An interview with Irl Hirsch, MD, about the results of the INHALE-3 Trial, which covers an inhaled insulin formulation. The potential cost compared to injectable insulin will also be discussed.
• A session on the SELECT Trial will be covered, which will include an overview of the study as well as semaglutide in individuals with vascular disease and prediabetes progression/regression. Further, the presenters will cover the role of glycemia on cardiovascular outcomes and heart failure and inflammation outcomes of the trial. Presenters will include Darren K. McGuire, MD, MHSc, FAHA, FACC, FESC, Donna H. Ryan, MD, Steven E. Kahn, MB, ChB, Ildiko Lingvay, MD, MPH, MSCS, Jorge Plutzky, MD, and Shivani Misra, MD, PhD.
• An interview with Timothy Garvey on the impact of celebrity influence over GLP-1 medications. The interview will include how the media attention will impact the perception and use of these medications and how to promote a more balanced conversation about GLP-1 medication, emphasizing the uses for type 2 diabetes while acknowledging the potential application in weight loss.
• A presentation on the results from the Flow Trial, investigating GLP-1s and their effect on first dedicated kidney outcomes. The session will include current treatment strategies and unmet needs, the trial design, the trial outcomes on kidney and cardiovascular disease, and results of baseline use of SGLT2i. Presenters will include Richard E. Pratley, MD, Vlado Perkovic, MBBS, PhD, FRACP, FASN, FAHMS, Peter Rossing, MD, DMSc, Kenneth W. Mahaffey, MD, PhD, Johannes F. Mann, MD, Katherine R. Tuttle, MD, FACP, FASN, FNKF, and Sylvia Rosas, MD, MSCE.

Follow Pharmacy Times for coverage of the conference on our website and on social media for the latest updates.